Anika reports inducement grants under nasdaq listing rule 5635(c)(4)

Bedford, mass., june 07, 2024 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global joint preservation company in early intervention orthopedics, today announced that on june 3, 2024, anika granted: (i) non-statutory stock options (“options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the nasdaq global select market (“closing price”) on the grant date, and (ii) restricted stock units (“rsus”) covering 38,520 shares of common stock, to stephen griffin, the company's recently appointed executive vice president, chief financial officer and treasurer. the grants were made pursuant to the anika therapeutics, inc. 2021 inducement plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with nasdaq listing rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with anika as a component of the grantee's employment compensation.
ANIK Ratings Summary
ANIK Quant Ranking